In a report issued on January 19, Eric Coldwell from Robert W. Baird maintained a Buy rating on Owens & Minor (OMI – Research Report), with a price target of $68.00. The company’s shares closed last Thursday at $41.82.
According to TipRanks.com, Coldwell is a 5-star analyst with an average return of 13.5% and a 61.5% success rate. Coldwell covers the Healthcare sector, focusing on stocks such as Quest Diagnostics, AmerisourceBergen, and Cardinal Health.
Currently, the analyst consensus on Owens & Minor is a Strong Buy with an average price target of $55.00, a 32.1% upside from current levels. In a report issued on January 5, Bank of America Securities also maintained a Buy rating on the stock with a $55.00 price target.
Based on Owens & Minor’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.5 billion and net profit of $44.13 million. In comparison, last year the company earned revenue of $2.19 billion and had a net profit of $46.08 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Owens & Minor, Inc. is a global healthcare solutions company. It integrates technologies, products, and services aligned to deliver significant and sustained value for healthcare providers and manufacturers across the continuum of care. The firm has distribution, production, customer service and sales facilities located across the Asia Pacific region, Europe, Latin America, and North America. The company was founded by Otho O. Owens and G. Gilmer Minor in 1882 and is headquartered in Mechanicsville, VA.
Read More on OMI:
- Robert W. Baird Maintains Their Buy Rating on Walgreens Boots Alliance (WBA)
- Robert W. Baird Maintains a Hold Rating on CVS Health (CVS)
- Robert W. Baird Maintains a Hold Rating on Trex Company (TREX)
- Robert W. Baird Maintains a Hold Rating on Fortune Brands (FBHS)
- Robert W. Baird Maintains Their Buy Rating on Syneos Health (SYNH)